Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 7/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.50 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.50 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203979 | 1.00 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL5240331 | 0.82 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL6205627 | 0.82 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL5238675 | 0.81 | CHRNB4 (0.60) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL6203538 | 0.81 | CHRNB4 (0.60) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL22106451 | 0.79 | CHRNB4 (0.54) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL5239389 | 0.76 | CHRNB4 (0.64) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL9241457 | 0.73 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL9238572 | 0.73 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL9238568 | 0.73 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507776-B1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7119111-B2 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | CHRNB4 4173/4885CHRNA3 4021/4885CHRNB2 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.